Primary |
Prophylaxis |
28.6% |
Pulmonary Hypertension |
22.8% |
Acute Respiratory Distress Syndrome |
6.3% |
Persistent Foetal Circulation |
5.3% |
Hypoxia |
4.9% |
Product Used For Unknown Indication |
4.9% |
Oxygen Saturation Decreased |
4.4% |
Pulmonary Arterial Hypertension |
3.4% |
Pulmonary Arterial Pressure Increased |
2.9% |
Respiratory Failure |
2.4% |
Sickle Cell Anaemia |
2.4% |
Neonatal Respiratory Distress Syndrome |
1.9% |
Bronchopulmonary Dysplasia |
1.5% |
Medical Device Implantation |
1.5% |
Premature Baby |
1.5% |
Ventricular Assist Device Insertion |
1.5% |
Acute Respiratory Failure |
1.0% |
Congenital Diaphragmatic Hernia |
1.0% |
Lung Disorder |
1.0% |
Myocardial Infarction |
1.0% |
|
Oxygen Saturation Decreased |
21.8% |
Device Failure |
11.3% |
Death |
7.5% |
Cardio-respiratory Arrest |
6.8% |
Patent Ductus Arteriosus |
6.8% |
Device Malfunction |
4.5% |
General Physical Health Deterioration |
4.5% |
Intraventricular Haemorrhage Neonatal |
3.8% |
Pulmonary Haemorrhage |
3.8% |
Cardiac Arrest |
3.0% |
Cognitive Disorder |
3.0% |
Drug Ineffective |
3.0% |
Off Label Use |
3.0% |
Respiratory Failure |
3.0% |
Sepsis Neonatal |
3.0% |
Hypotension |
2.3% |
Neonatal Disorder |
2.3% |
Neonatal Hypotension |
2.3% |
No Therapeutic Response |
2.3% |
Pneumothorax |
2.3% |
|
Secondary |
Pulmonary Hypertension |
36.0% |
Prophylaxis |
10.0% |
Hypoxia |
8.0% |
Oxygen Saturation Decreased |
8.0% |
Product Used For Unknown Indication |
6.0% |
Acute Respiratory Distress Syndrome |
4.0% |
Acute Respiratory Failure |
4.0% |
Neonatal Aspiration |
4.0% |
Neonatal Respiratory Distress Syndrome |
4.0% |
Oxygen Supplementation |
4.0% |
Persistent Foetal Circulation |
4.0% |
Bronchopulmonary Dysplasia |
2.0% |
Lung Disorder |
2.0% |
Pulmonary Arterial Pressure Increased |
2.0% |
Venous Oxygen Saturation |
2.0% |
|
Oxygen Saturation Decreased |
35.0% |
Device Failure |
17.5% |
Medical Device Complication |
5.0% |
Sepsis |
5.0% |
Cardio-respiratory Arrest |
2.5% |
Central Venous Pressure Increased |
2.5% |
Congenital Cystic Kidney Disease |
2.5% |
Device Malfunction |
2.5% |
Device Misuse |
2.5% |
Disease Progression |
2.5% |
Drug Administration Error |
2.5% |
Hypotension |
2.5% |
Multi-organ Failure |
2.5% |
Neonatal Disorder |
2.5% |
Neonatal Hypoxia |
2.5% |
Patent Ductus Arteriosus |
2.5% |
Renal Disorder |
2.5% |
Ventricular Fibrillation |
2.5% |
White Blood Cell Count Decreased |
2.5% |
|
Concomitant |
Pulmonary Hypertension |
20.0% |
Prophylaxis |
16.0% |
Arrhythmia |
8.0% |
Hypotension |
8.0% |
Product Used For Unknown Indication |
8.0% |
Sedation |
8.0% |
Analgesic Therapy |
4.0% |
Cardiac Disorder |
4.0% |
Cardiac Failure High Output |
4.0% |
Cardiac Output |
4.0% |
Coronary Artery Bypass |
4.0% |
Patent Ductus Arteriosus |
4.0% |
Tardive Dyskinesia |
4.0% |
Ventricular Assist Device Insertion |
4.0% |
|
Renal Failure |
25.0% |
Ill-defined Disorder |
12.5% |
Post Procedural Haemorrhage |
12.5% |
Pulmonary Hypertension |
12.5% |
Pulmonary Interstitial Emphysema Syndrome |
12.5% |
Respiratory Acidosis |
12.5% |
Therapy Non-responder |
12.5% |
|